Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in advanced TNBC
NCT02929576Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Sep 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enzalutamide in triple-negative breast cancer (TNBC) (3 arms), sponsored by Pfizer. Primary endpoint: Progression Free Survival at 31 months. Planned start Sep 2016; status: withdrawn.
02
Drugs
enzalutamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02929576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929576.